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PET/CT has emerged as an important tool in oncology
to detect, characterize, and follow-up various tumor
entities. The integrated technology includes the respec-
tive advantageousness of PET and CT in a synergistic
manner combining high sensitivity of PET with trans-
mission correction and anatomic referencing by CT.
PET/CT has been proven to be fast, robust and mean-
while widely available in oncologic centers. But for sev-
eral tumor entities, e.g. cancers of the brain, liver, cervix
or prostate, MRI would be beneficial compared to CT
due to the superior soft tissue contrast and additionally
functional information about e.g. tumor perfusion (DCE,
T2*) and diffusion (DWI). On the other hand, sequential
MR and PET/CT imaging has several limitations: patient
repositioning may result in spatial mismatch and the
various ways of the correction of misalignment are time
consuming and limited; it is furthermore uncomfortable
for critically ill patients, costly in terms of time and per-
sonal resources and inefficient from a work-flow per-
spective. Scientific and clinical considerations therefore
argue for the benefits of simultaneous coregistration of
MR and PET imaging in oncology. Simultaneous PET/
MR furthermore reduces the X-ray exposures of the
patients, which is an important issue particularly for
young patients and patients who need multiple follow-
up examinations.
Sequential and fully integrated whole-body 3.0 Tesla
PET/MR scanners are meanwhile available from Philips,
Siemens and GE. Initial limitations of the simultaneous
PET/MR technology concerning the attenuation correc-
tion with MR alone have been extensively addressed.
PET image reconstruction with accurate attenuation
correction as well as quantification of local radiotracer
uptake, i.e. calculation of the SUV, is now possible using
the MR data [1]. Furthermore, simultaneous temporal
and spatial coregistration of PET and MR data has also
been successfully applied for MRI-gated PET measure-
ments of moving organs/tumors in e.g. bronchial or
liver cancer [2]. Initial feasibility studies have proven
that PET/MR imaging can be advantages for tumor
detection, staging as well as for therapy monitoring and
follow-up in e.g. lung cancer, head and neck cancers,
breast cancer, liver cancer, prostate cancer, lymphoma,
seminal carcinoma etc. [3-7]. Beneficial applications are
in particular for comprehensive management of solid
tumors in children concerning tumor detection, charac-
terization as well as treatment monitoring [8]. Promising
applications have been published in particular for prostate
cancer concerning whole-body PET/MR with 68Ga-
labelled prostate-specific membrane antigen (PSMA)
ligand [9].
But despite an increasing body of knowledge about the
application of sequential and simultaneous PET/MR in
oncology various open questions still exist concerning
the scientific and medical prospects and limitations.
What unmet radiological needs are addressed by PET/
MR from a scientific and clinical point of view? Is a
hardware integration of PET and MR actually required
from a clinical point of view? What are the clinical indi-
cations in which simultaneous PET/MR achieves higher
diagnostic accuracy compared to subsequent MR and
PET/CT imaging? Could sequential PET/CT and MR
imaging followed by software-based image coregistration
be sufficient in particular clinical situations? What are
the essential added values of PET/MR compared to
PET/CT? Can PET/MR be economically reasonable and
reduce overall costs for therapy planning monitoring
and follow-up?
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